1. Scrip
  2. >>Therapy Areas
  3. >>Sensory

Phase II Data May Be Good Sign For 8mg Aflibercept, But Will Payers Bite?

 
• By Alaric DeArment

There are concerns that even with better efficacy and dosing versus Eylea and biosimilars, payers may impose step-edits on Regeneron’s new high-dose version.

Female eye with long eyelashes close up. Closeup shot of female gray - blue colour eye with day makeup. Beauty female eye with curl long eyelashes
Regeneron announced Phase II data for aflibercept 8mg in wet AMD • Source: Shutterstock

Phase II data for Regeneron Pharmaceuticals, Inc.’s high-dose version of aflibercept appear to bode well for a Phase III readout expected later this year and give it a decent shot at competing against other newer drugs for wet age-related macular degeneration (AMD). Still, there is a chance that it could run up against restrictions in insurance coverage, based on concerns that physicians have previously expressed.

The Phase II CANDELA study, presented at the Angiogenesis 2022 meeting on 12 February, met its primary safety endpoint with no new safety signals through week 44 compared with Eylea (aflibercept)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Sensory

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 
• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

In Brief: US FDA Rejects Regeneron’s Bid to Extend Eylea HD Dosing

 
• By Sushmita Panda

Regeneron is disappointed by the knock-back for longer dosing intervals for its high-dose version of Eylea, but its supplemental application for a more commercially important shorter four-week regimen has received a priority review.

Outlook Holds Out Hope For Wet AMD Approval Despite Phase III Topline Miss

 
• By Alaric DeArment

The company said the NORSE EIGHT trial of ONS-5010 did not meet the primary endpoint of showing noninferiority to ranibizumab, but it still plans to file for US FDA approval.

GSK’s Linerixibat GLISTENs In PBC Itching

 
• By Elizabeth Cairns

But differences in trial design means it is hard to handicap GSK’s product against Mirum’s volixibat.

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.